Magenta Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MGTA research report →
Companywww.magentatx.com
Magenta Therapeutics, Inc. , a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants.
- CEO
- Stephen F. Mahoney MBA
- IPO
- 2018
- Employees
- 67
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $42.44M
- P/E
- -0.02
- P/S
- 48.62
- P/B
- 0.00
- EV/EBITDA
- 3.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- -21911.68%
- Net Margin
- -19892.33%
- ROE
- -27.30%
- ROIC
- -15.82%
Growth & Income
- Revenue
- $2.04M · -67.35%
- Net Income
- $-162,337,000 · -91.05%
- EPS
- $0.00 · 100.00%
- Op Income
- $-177,933,000
- FCF YoY
- -65.13%
Performance & Tape
- 52W High
- $1.81
- 52W Low
- $0.32
- 50D MA
- $0.78
- 200D MA
- $0.73
- Beta
- 2.11
- Avg Volume
- 247.98K
Get TickerSpark's AI analysis on MGTA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 29, 23 | Fairmount Funds Management LLC | buy | 24,670 |
| Sep 26, 23 | Fairmount Funds Management LLC | buy | 30,000 |
| Sep 22, 23 | Randhawa Simrat | buy | 2,000 |
| Sep 21, 23 | Randhawa Simrat | buy | 2,000 |
| Sep 19, 23 | Fairmount Funds Management LLC | buy | 30,000 |
| Sep 11, 23 | Meng Lei | other | 6,500 |
| Sep 11, 23 | Meng Lei | other | 0 |
| Sep 11, 23 | Violin Jonathan | other | 6,500 |
| Sep 13, 23 | Fairmount Funds Management LLC | buy | 9,367 |
| Sep 12, 23 | Fairmount Funds Management LLC | buy | 14,887 |
Our MGTA Coverage
We haven't published any research on MGTA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MGTA Report →